Literature DB >> 1867519

The prognosis of melanoma patients with metastases to two or more lymph node areas.

R J Barth1, D J Venzon, A R Baker.   

Abstract

The prognosis of melanoma patients who present with metastatic involvement of two or more noncontiguous lymph node regions before the detection of extranodal metastases has not been previously reported. We identified 21 patients with metastatic melanoma in at least two nodal basins in a review of 175 patients with melanoma undergoing lymphadenectomy at the National Cancer Institute. The median survival time of these patients was 46 months, with 55%, 27%, and 17% of the patients alive 2, 5, and 10 years, respectively, after the second lymphadenectomy. Because the prognosis of melanoma patients with metastases to two or more regional nodal areas appears equivalent to that of patients with metastatic involvement of only one regional node site, lymphadenectomy of the involved groups should be performed with therapeutically curative intent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867519      PMCID: PMC1358511          DOI: 10.1097/00000658-199108000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  PROGNOSIS IN MALIGNANT MELANOMA.

Authors:  G MACNEER; T DASGUPTA
Journal:  Surgery       Date:  1964-09       Impact factor: 3.982

2.  Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience.

Authors:  C A Presant; A A Bartolucci
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860

3.  Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.

Authors:  R I Fisher; W D Terry; R J Hodes; S A Rosenberg; R Makuch; H G Gordon; S G Fisher
Journal:  Surg Clin North Am       Date:  1981-12       Impact factor: 2.741

4.  Epitrochlear node involvement in melanoma of the upper extremity.

Authors:  T J Smith; G M Sloan; A R Baker
Journal:  Cancer       Date:  1983-02-15       Impact factor: 6.860

5.  Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.

Authors:  C Callery; A J Cochran; D J Roe; W Rees; S D Nathanson; J K Benedetti; R M Elashoff; D L Morton
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

6.  Results of ilioinguinal dissection for stage II melanoma.

Authors:  S J Finck; A E Giuliano; B D Mann; D L Morton
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

7.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).

Authors:  C M Balch; S J Soong; T M Murad; J W Smith; W A Maddox; J R Durant
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

8.  Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases.

Authors:  A Calabro; S E Singletary; C M Balch
Journal:  Arch Surg       Date:  1989-09

9.  A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Ann Surg       Date:  1981-03       Impact factor: 12.969

10.  Prognosis of patients with pathologic stage II cutaneous malignant melanoma.

Authors:  D F Roses; J A Provet; M N Harris; S L Gumport; N Dubin
Journal:  Ann Surg       Date:  1985-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.